Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2011 2
2012 4
2013 2
2014 4
2015 6
2016 3
2017 7
2018 4
2019 5
2020 4
2021 3
2022 3
2023 5
2024 6
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.
Van den Eynde A, Gehrcken L, Verhezen T, Lau HW, Hermans C, Lambrechts H, Flieswasser T, Quatannens D, Roex G, Zwaenepoel K, Marcq E, Joye P, Cardenas De La Hoz E, Deben C, Gasparini A, Montay-Gruel P, Le Compte M, Lion E, Lardon F, Van Laere S, Siozopoulou V, Campillo-Davo D, De Waele J, Pauwels P, Jacobs J, Smits E, Van Audenaerde JRM. Van den Eynde A, et al. Among authors: lion e. J Hematol Oncol. 2024 Feb 9;17(1):8. doi: 10.1186/s13045-024-01525-w. J Hematol Oncol. 2024. PMID: 38331849 Free PMC article.
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Berneman ZN, De Laere M, Germonpré P, Huizing MT, Willemen Y, Lion E, De Reu H, Van den Bossche J, Van den Brande J, Specenier P, Altintas S, van Dam PA, Cools N, Nijs G, Stein B, Caluwaerts K, Snoeckx A, Op de Beeck B, Saevels K, Rutsaert L, Vandenbosch I, Oner G, Lammens M, Van Damme P, Llewellyn-Lacey S, Price DA, Oka Y, Oji Y, Sugiyama H, Couttenye MM, Van de Velde AL, Van Tendeloo VF, Peeters M, Anguille S, Smits ELJM. Berneman ZN, et al. Among authors: lion e. J Hematol Oncol. 2025 Jan 23;18(1):9. doi: 10.1186/s13045-025-01661-x. J Hematol Oncol. 2025. PMID: 39849594 Free PMC article. Clinical Trial.
DRP1 depletion protects NK cells from hypoxia-induced dysfunction.
Verhezen T, Van Den Eynde A, Verstraelen P, Gehrcken L, Palmiotto G, Lau HW, De Vos WH, Van Der Heijden S, Brants L, Melis J, Van Audenaerde J, Rodrigues Fortes F, Le Compte M, Roeyen G, Prenen H, Campillo-Davo D, Lion E, Argüello RJ, Van Laere S, Lardon F, Deben C, Wouters A, Smits E, De Waele J. Verhezen T, et al. Among authors: lion e. Redox Rep. 2026 Dec;31(1):2626181. doi: 10.1080/13510002.2026.2626181. Epub 2026 Feb 18. Redox Rep. 2026. PMID: 41706678 Free PMC article.
Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.
Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S. Van Acker HH, et al. Among authors: lion e. J Clin Med. 2019 Apr 27;8(5):579. doi: 10.3390/jcm8050579. J Clin Med. 2019. PMID: 31035598 Free PMC article. Review.
Clinical use of dendritic cells for cancer therapy.
Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Anguille S, et al. Among authors: lion e. Lancet Oncol. 2014 Jun;15(7):e257-67. doi: 10.1016/S1470-2045(13)70585-0. Lancet Oncol. 2014. PMID: 24872109 Review.
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.
Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN. Anguille S, et al. Among authors: lion e. Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456. Pharmacol Rev. 2015. PMID: 26240218 Review.
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Roex G, et al. Among authors: lion e. J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1. J Hematol Oncol. 2020. PMID: 33272302 Free PMC article.
69 results